[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
April 2004

Oral Pentoxifylline vs Topical Betamethasone in Schamberg Disease: A Comparative Randomized Investigator-Blinded Parallel-Group Trial

Arch Dermatol. 2004;140(4):491-493. doi:10.1001/archderm.140.4.491

Previous uncontrolled studies have suggested that pentoxifylline could be useful in the treatment of Schamberg disease (progressive purpuric pigmented dermatosis, PPPD).1,2 The objective of this randomized, investigator-blinded trial was to compare the clinical efficacies of oral pentoxifylline (Trental; Aventis, Mumbai, India) sustained-release dragées, 400 mg thrice daily, and topical betamethasone dipropionate cream, 0.05% wt/wt (Diprovate; Croslands, Pune, India) thin-film application locally twice daily. Steroids, topical and systemic, are credited with providing limited benefits and are commonly used to treat this condition.3

First Page Preview View Large
First page PDF preview
First page PDF preview
×